Personalised regenerative cell therapy for androgenic alopecia

雄激素性脱发的个性化再生细胞疗法

• 批准号: 105711
• 金额: $ 29.85万
• 依托单位: HAIRCLONE LIMITED
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105711
• 关键词: Personalised; regenerative; cell; therapy; androgenic

A significant proportion of men (70%) and women (40%) around the world experience hair loss at some time in their lives. The primary cause is a disease called androgenic alopecia and this results in affected hair follicles miniaturising, producing thinner, shorter hair shafts, which gives the appearance that the hair is lost. Over 1.8 million people around the world seek surgical and non-surgical treatments for hair loss. This project brings together leading scientists and clinicians who will build on prior pre-clinical and clinical data to develop a treatment that uses cultured cells from a few unaffected hair follicles to rebuild thousands of these miniaturising hairs and permanently reverse the appearance of hair loss. For many people, hair restoration treatment would have a big impact on their confidence and quality of life. This also presents a huge market opportunity for the UK and it would be the first real indication that a mini-organ structure could be regenerated which would have a much wider impact on strategies used in other regenerative medicines.

全世界有相当比例的男性（70%）和女性（40%）在一生中的某个时候经历过脱发。主要原因是一种叫做雄激素性脱发的疾病，这会导致受影响的毛囊变细，产生更薄，更短的毛干，这给人的感觉是头发丢失了。全世界有超过180万人寻求手术和非手术治疗脱发。该项目汇集了领先的科学家和临床医生，他们将建立在先前的临床前和临床数据的基础上，开发一种治疗方法，使用来自少数未受影响的毛囊的培养细胞来重建数千根这些正在生长的头发，并永久扭转脱发的外观。对于许多人来说，头发修复治疗会对他们的信心和生活质量产生很大的影响。这也为英国带来了巨大的市场机会，这将是第一个真实的迹象表明，微型器官结构可以再生，这将对其他再生药物中使用的策略产生更广泛的影响。